Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
WYETH ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
WYETH Mar-14 |
ADCOCK INGRAM Jun-14 |
WYETH/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,065 | 320 | - | |
Low | Rs | 553 | 231 | - | |
Sales per share (Unadj.) | Rs | 289.5 | 95.3 | - | |
Earnings per share (Unadj.) | Rs | 38.7 | -24.0 | - | |
Cash flow per share (Unadj.) | Rs | 39.9 | -19.9 | - | |
Dividends per share (Unadj.) | Rs | 145.00 | 0 | - | |
Avg Dividend yield | % | 17.9 | 0 | - | |
Book value per share (Unadj.) | Rs | 118.5 | 74.8 | - | |
Shares outstanding (eoy) | m | 22.72 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.8 | 2.9 | 96.6% | |
Avg P/E ratio | x | 20.9 | -11.5 | -182.1% | |
P/CF ratio (eoy) | x | 20.3 | -13.9 | -146.3% | |
Price / Book Value ratio | x | 6.8 | 3.7 | 185.2% | |
Dividend payout | % | 374.7 | 0 | - | |
Avg Mkt Cap | Rs m | 18,381 | 46,551 | 39.5% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 359 | 2,922 | 12.3% | |
Avg. sales/employee | Rs Th | 0 | 3,747.7 | - | |
Avg. wages/employee | Rs Th | 0 | 680.6 | - | |
Avg. net profit/employee | Rs Th | 0 | -944.3 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 6,577 | 16,089 | 40.9% | |
Other income | Rs m | 347 | 113 | 308.3% | |
Total revenues | Rs m | 6,925 | 16,201 | 42.7% | |
Gross profit | Rs m | 1,023 | -2,788 | -36.7% | |
Depreciation | Rs m | 27 | 694 | 3.9% | |
Interest | Rs m | 4 | 436 | 1.0% | |
Profit before tax | Rs m | 1,339 | -3,806 | -35.2% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 460 | 238 | 193.3% | |
Profit after tax | Rs m | 879 | -4,054 | -21.7% | |
Gross profit margin | % | 15.6 | -17.3 | -89.8% | |
Effective tax rate | % | 34.3 | -6.2 | -549.4% | |
Net profit margin | % | 13.4 | -25.2 | -53.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,964 | 11,784 | 33.6% | |
Current liabilities | Rs m | 2,081 | 6,630 | 31.4% | |
Net working cap to sales | % | 28.6 | 32.0 | 89.4% | |
Current ratio | x | 1.9 | 1.8 | 107.2% | |
Inventory Days | Days | 35 | 111 | 31.6% | |
Debtors Days | Days | 278 | 124 | 224.0% | |
Net fixed assets | Rs m | 878 | 6,869 | 12.8% | |
Share capital | Rs m | 227 | 75 | 304.2% | |
Net worth | Rs m | 2,693 | 12,628 | 21.3% | |
Long term debt | Rs m | 25 | 4,438 | 0.6% | |
Total assets | Rs m | 4,842 | 23,855 | 20.3% | |
Interest coverage | x | 306.0 | -7.7 | -3,957.1% | |
Debt to equity ratio | x | 0 | 0.4 | 2.6% | |
Sales to assets ratio | x | 1.4 | 0.7 | 201.4% | |
Return on assets | % | 18.2 | -15.2 | -120.3% | |
Return on equity | % | 32.6 | -32.1 | -101.7% | |
Return on capital | % | 49.4 | -19.8 | -249.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,188 | 1,373 | 86.5% | |
From Investments | Rs m | 287 | -422 | -68.0% | |
From Financial Activity | Rs m | -4,296 | 4,028 | -106.7% | |
Net Cashflow | Rs m | -2,821 | 4,979 | -56.7% |
Compare WYETH With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare WYETH With: GRANULES INDIA CHANDRA BHAGAT PHARMA ADVANCED ENZYME TECHNOLOGIES EARUM PHARMACEUTICALS KOPRAN.
On Monday, Indian share markets reversed the trend as the session progressed and ended the day higher.